

## **FINAL PROFESSIONAL INFORMATION**

### **SCHEDULING STATUS**

**S4**

#### **1. NAME OF THE MEDICINE**

**Bicalutamide 150 Accord**

(Film-coated Tablets)

#### **2. QUALITATIVE AND QUANTITATIVE COMPOSITION**

Each film-coated tablet contains 150 mg bicalutamide.

Contains sugar: Lactose monohydrate

**Excipients:** Sodium starch glycolate, Povidone K-30, Sodium starch glycolate, Magnesium stearate which make up the tablet core and Hypromellose, Titanium dioxide, Macrogol 400 which make up the film-coat.

For the full list of excipients, see section 6.1.

#### **3. PHARMACEUTICAL FORM**

Film-coated tablets

White to off white, round, biconvex, film coated tablets debossed 'l01' on one side and plain on other side.

#### **4. CLINICAL PARTICULARS**

##### **4.1 Therapeutic indications**

In patients with locally advanced prostate cancer (T3-4, any N, M0/T1-2, N+, M0) Bicalutamide 150 Accord is indicated as immediate therapy either alone or as adjuvant to treatment by radical prostatectomy or radiotherapy.

Bicalutamide 150 Accord is indicated as monotherapy for the management of patients with locally

### **FINAL PROFESSIONAL INFORMATION**

advanced, non-metastatic prostate cancer for whom surgical or medical castration is not appropriate.

#### **4.2 Posology and method of administration**

##### **Posology**

Adult males including the elderly: 1 tablet (150 mg) once a day. For 2 years or until progression.

Renal impairment: no dosage adjustment is necessary for patients with renal impairment.

Hepatic impairment: no dosage adjustment is necessary for patients with mild hepatic impairment. Increased accumulation may occur in patients with moderate to severe hepatic impairment (see section 4.4).

#### **4.3 Contraindications**

Bicalutamide 150 Accord is contraindicated in females and children.

Bicalutamide 150 Accord must not be given to any patient who has shown a hypersensitivity reaction to the bicalutamide or to any of the excipients of Bicalutamide 150 Accord.

Co-administration of terfenadine, astemizole or cisapride.

#### **4.4 Special warnings and precautions for use**

Initiation of treatment should be under the direct supervision of a specialist.

Bicalutamide is extensively metabolised in the liver. Data suggest that its elimination may be slower in subjects with severe hepatic impairment and this could lead to increased accumulation of bicalutamide. Therefore, Bicalutamide 150 Accord should be used with caution in patients with moderate to severe hepatic impairment.

Periodic liver function testing should be considered due to the possibility of hepatic changes. The majority of changes are expected to occur within the first 6 months of Bicalutamide 150 Accord

### **FINAL PROFESSIONAL INFORMATION**

therapy.

Severe hepatic changes and hepatic failure have been observed with Bicalutamide 150 Accord, and fatal outcomes have been reported (see section 4.8). Bicalutamide 150 Accord therapy should be discontinued if changes are severe.

For patients who have an objective progression of disease together with elevated PSA, cessation of Bicalutamide 150 Accord therapy should be considered.

Clinically discontinuation of Bicalutamide 150 Accord can result in anti-androgen withdrawal syndrome in a subset of patients. This is characterised by a decline in PSA (prostate specific antigen) or clinical response following withdrawal of the anti-androgen component of Maximal Androgen Blockade (MAB). This syndrome has been well described in scientific literature although the pathophysiology is unknown and may reflect multiple mechanisms, but it is believed to represent the development of agonistic activity by the medicine at the receptor level due to receptor mutations with advancing disease. Although this effect has only been reported with the 50 mg dose (approved for use in combination therapy), given the likely mode of action the phenomenon could theoretically occur with the 150 mg dose used as single agent therapy. Bicalutamide has been shown to inhibit cytochrome P450 (CYP3A4), as such, caution should be exercised when co-administered with medicines metabolised predominantly by CYP 3A4 (see sections 4.3 and 4.5).

Less frequently, photosensitivity reactions have been reported for patients taking Bicalutamide 150 Accord. Patients should be advised to avoid direct exposure to excessive sunlight or UV-light while on Bicalutamide 150 Accord and the use of sunscreens may be considered. In cases where the photosensitivity reaction is more persistent and/or severe, an appropriate symptomatic treatment

### **FINAL PROFESSIONAL INFORMATION**

should be initiated.

The product contains lactose. Patients with rare hereditary problems of galactose intolerance, total lactase deficiency or glucose-galactose malabsorption should not take this medicine.

Androgen deprivation therapy may prolong the QT interval.

In patients with a history of or risk factors for QT prolongation and in patients receiving concomitant medicinal products that might prolong the QT interval (see section 4.5) physicians should assess the benefit risk ratio including the potential for Torsade de pointes prior to initiating Bicalutamide 150 Accord.

Antiandrogen therapy may cause morphological changes in spermatozoa. Although the effect of bicalutamide on sperm morphology has not been evaluated and no such changes have been reported for patients who received Bicalutamide 150 Accord, patients and/or their partners should follow adequate contraception during and for 130 days after Bicalutamide 150 Accord therapy.

Potentiation of coumarin anticoagulant effects have been reported in patients receiving concomitant Bicalutamide 150 Accord therapy, which may result in increased Prothrombin Time (PT) and International Normalised Ratio (INR). Some cases have been associated with risk of bleeding. Close monitoring of PT/INR is advised and anticoagulant dose adjustment should be considered (see sections 4.5 and 4.8).

#### **4.5 Interaction with other medicinal products and other forms of interaction**

*In vitro* studies have shown that R-bicalutamide is an inhibitor of CYP 3A4, with lesser inhibitory effects on CYP 2C9, 2C19 and 2D6 activity. Although clinical studies using antipyrine as a marker of cytochrome P450 (CYP) activity showed no evidence of a drug interaction potential with

### **FINAL PROFESSIONAL INFORMATION**

Bicalutamide 150 Accord, mean midazolam exposure (AUC) was increased by up to 80% after co-administration of Bicalutamide 150 Accord for 28 days. For drugs with a narrow therapeutic index such an increase could be of relevance. As such, concomitant use of terfenadine, astemizole and cisapride is contraindicated (see section 4.3) and caution should be exercised with the co-administration of Bicalutamide 150 Accord with compounds such as ciclosporin and calcium channel blockers. Dosage reduction may be required for these drugs particularly if there is evidence of enhanced or adverse drug effect. For ciclosporin, it is recommended that plasma concentrations and clinical condition are closely monitored following initiation or cessation of Bicalutamide 150 Accord therapy.

Caution should be exercised when prescribing Bicalutamide 150 Accord with other drugs which may inhibit drug oxidation e.g. cimetidine and ketoconazole. In theory, this could result in increased plasma concentrations of bicalutamide which theoretically could lead to an increase in side effects.

*In vitro* studies have shown that bicalutamide can displace the coumarin anticoagulant, warfarin, from its protein binding sites. There have been reports of increased effect of warfarin and other coumarin anticoagulants when co-administered with Bicalutamide 150 Accord. It is therefore recommended that if Bicalutamide 150 Accord is administered in patients who are concomitantly receiving coumarin anticoagulants, PT/INR should be closely monitored and adjustments of anticoagulant dose considered (see sections 4.4 and 4.8).

Since androgen deprivation treatment may prolong the QT interval, the concomitant use of Bicalutamide 150 Accord with medicinal products known to prolong the QT interval or medicinal products able to induce Torsade de pointes such as class IA (e.g. quinidine, disopyramide) or class III (e.g. amiodarone, sotalol, dofetilide, ibutilide) antidysrhythmic medicinal products, methadone, moxifloxacin, antipsychotics, etc. should be carefully evaluated (see section 4.4).

## **FINAL PROFESSIONAL INFORMATION**

### **Paediatric population**

Interaction studies have only been performed in adults.

## **4.6 Fertility, pregnancy and lactation**

### **Pregnancy**

Bicalutamide is contraindicated in females and must not be given to pregnant women.

### **Breast-feeding**

Bicalutamide is contraindicated during breast-feeding.

### **Fertility**

Reversible impairment of male fertility has been observed in animal studies (see section 5.3). A period of subfertility or infertility should be assumed in man.

## **4.7 Effects on ability to drive and use machines**

During treatment with Bicalutamide 150 Accord, somnolence has been reported in patients who experience this symptom should not drive or use machine.

## **4.8 Undesirable effects**

In this section, undesirable effects are defined as follows: frequency unknown (cannot be estimated from the available data).

**FINAL PROFESSIONAL INFORMATION**

**Table 1: Frequency of Adverse Reactions**

<b>SYSTEM ORGAN CLASS</b>	<b>Frequency</b>	<b>Event</b>
Blood and the lymphatic system disorders	Frequent	Anaemia
Immune system disorders	Less frequent	Hypersensitivity, angioedema and urticaria
Metabolism and nutrition disorders	Frequent	Decreased appetite
Psychiatric disorders	Frequent	Decreased libido, Depression
Nervous system disorders	Frequent	Dizziness, Somnolence
Cardiac disorders	Frequency unknown	QT prolongation (see sections 4.4 and 4.5)
Vascular disorders	Frequent	Hot flush

**FINAL PROFESSIONAL INFORMATION**

Respiratory, thoracic and mediastinal disorders	Less frequent	Interstitial lung disease <sup>e</sup> (fatal outcomes have been reported).
Gastrointestinal disorders	Frequent	Abdominal, pain, Constipation, Dyspepsia, Flatulence, Nausea
Hepato-biliary disorders	Frequent	Hepatotoxicity, jaundice, hypertransaminasaemia <sup>a</sup>
	Less frequent	Hepatic failure <sup>d</sup> (fatal outcomes have been reported).
Skin and subcutaneous tissue disorders	Frequent	Rash, Alopecia, Hirsutism/hair re-growth, Dry skin <sup>c</sup> Pruritus
	Less frequent	Photosensitivity reaction
Reproductive system and breast disorders	frequent	Erectile dysfunction, Gynaecomastia and breast tenderness <sup>b</sup>



**FINAL PROFESSIONAL INFORMATION**

General disorders and administration site conditions	Frequent	Chest pain, Oedema, Asthenia
Investigations	Frequent	Weight increased

- a. Hepatic changes are rarely severe and were frequently transient, resolving or improving with continued therapy or following cessation of therapy.
- b. The majority of patients receiving Bicalutamide 150 Accord as monotherapy experience gynaecomastia and/or breast pain. In studies these symptoms were considered to be severe in up to 5% of the patients. Gynaecomastia may not resolve spontaneously following cessation of therapy, particularly after prolonged treatment.
- c. Due to the coding conventions used in the EPC studies, adverse events of 'dry skin' were coded under the COSTART term of 'rash'. No separate frequency descriptor can therefore be determined for the 150 mg Bicalutamide 150 Accord dose however the same frequency as the 50 mg dose is assumed.
- d. Listed as an adverse drug reaction following review of post-marketed data. Frequency has been determined from the incidence of reported adverse events of hepatic failure in patients receiving treatment in the open-label Bicalutamide 150 Accord arm of the 150 mg EPC studies.
- e. Listed as an adverse drug reaction following review of post-marketed data. Frequency has been determined from the incidence of reported adverse events of interstitial pneumonia in the randomised treatment period of the 150 mg EPC studies.

Increased PT/INR: Accounts of coumarin anticoagulants interacting with Bicalutamide 150 Accord have been reported in post-marketing surveillance (see sections 4.4 and 4.5).

Reporting of suspected adverse reactions

Reporting suspected adverse reactions after authorisation of the medicine is important. It allows continued monitoring of the benefit/risk balance of the medicine. Healthcare professionals are

SAHPRA CLINICAL TEMPLATE 07/2020  
Applicant/HCR: Accord Healthcare (Pty) Ltd  
Bicalutamide 150 Accord, Film coated tablet (Bicalutamide)  
Strength: 150 mg

### **FINAL PROFESSIONAL INFORMATION**

asked to report any suspected adverse reactions to SAHPRA via the “**6.04 Adverse Drug Reactions Reporting Form**”, found online under SAHPRA’s publications:

<https://www.sahpra.org.za/Publications/Index/8>

#### **4.9 Overdose**

There is no human experience of overdosage. There is no specific antidote; treatment should be symptomatic. Dialysis may not be helpful, since bicalutamide is highly protein bound and is not recovered unchanged in the urine. General supportive care, including frequent monitoring of vital signs, is indicated.

### **5. PHARMACOLOGICAL PROPERTIES**

#### **5.1 Pharmacodynamic properties**

Pharmacotherapeutic group: Antiandrogen, ATC code L02 B B03

##### Mechanism of action

Bicalutamide is a non-steroidal antiandrogen, devoid of other endocrine activity. It binds to the wild type or normal androgen receptor without activating gene expression, and thus inhibits the androgen stimulus. Regression of prostatic tumours results from this inhibition. Clinically, discontinuation of Bicalutamide 150 Accord can result in the 'antiandrogen withdrawal syndrome' in a subset of patients.

Bicalutamide is a racemate with its anti-androgenic activity being almost exclusively in the (R)-enantiomer.

##### *Pharmacokinetic properties:*

Bicalutamide is well absorbed following oral administration. There is no evidence of any clinically relevant effect of food on bioavailability.

The (S)-enantiomer is rapidly cleared relative to the (R)-enantiomer, the latter having a plasma elimination half-life of about 1 week.

### **FINAL PROFESSIONAL INFORMATION**

On daily administration of Bicalutamide 150 Accord, the (R)-enantiomer accumulates about 10-fold in plasma as a consequence of its long half-life.

Steady state plasma concentrations of the (R)-enantiomer of approximately 22 µg/ml are observed during daily administration of 150 mg doses of Bicalutamide 150 Accord. At steady state the predominantly active (R)-enantiomer accounts for 99 % of the total circulating enantiomers.

The pharmacokinetics of the (R)-enantiomer are unaffected by age, renal impairment or mild to moderate hepatic impairment. There is evidence that for subjects with severe hepatic impairment, the (R)-enantiomer is more slowly eliminated from plasma.

Bicalutamide is highly protein bound (racemate 96 %, (R)-enantiomer > 99 %) and extensively metabolised (via oxidation and glucuronidation); its metabolites are eliminated via the kidneys and bile in approximately equal proportions.

In a clinical study the mean concentration of R-bicalutamide in semen of men receiving Bicalutamide 150 Accord was 4,9 µg/ml. The amount of bicalutamide potentially delivered to a female partner during intercourse equates to approximately 0,3 µg/kg.

Bicalutamide is a potent anti-androgen and a mixed function oxidase enzyme inducer in animals.

Target organ changes, including tumour induction, in animals, are related to these activities.

None of the findings in pre-clinical testing is considered to have relevance to the treatment of advanced prostate cancer patients.

## **5.2 Pharmacokinetic properties**

### *Absorption*

Bicalutamide is well absorbed following oral administration. There is no evidence of any clinically

### **FINAL PROFESSIONAL INFORMATION**

relevant effect of food on bioavailability.

Steady state plasma concentrations of the (R)-enantiomer, of approximately 22 microgram/ml are observed during daily administration of Bicalutamide 150 Accord. At steady state, the predominantly active (R)-enantiomer accounts for 99% of the total circulating enantiomers.

#### *Distribution and biotransformation*

Bicalutamide is highly protein bound (racemate 96%, (R)-enantiomer >99%) and extensively metabolised (oxidation and glucuronidation); its metabolites are eliminated via the kidneys and bile in approximately equal proportions.

In a clinical study, the mean concentration of R-bicalutamide in semen of men receiving Bicalutamide 150 Accord was 4.9 microgram/ml. The amount of bicalutamide potentially delivered to a female partner during intercourse is low and equates to approximately 0.3 microgram/kg. This is below that required to induce changes in offspring of laboratory animals.

#### *Elimination*

The (S)-enantiomer is rapidly cleared relative to (R)-enantiomer, the latter having a plasma elimination half-life of about 1 week.

On daily administration of Bicalutamide 150 Accord, the (R)-enantiomer accumulates about 10-fold in plasma as a consequence of its long half-life.

#### *Special populations*

The pharmacokinetics of the (R)-enantiomer are unaffected by age, renal impairment or mild to moderate hepatic impairment. There is evidence that for subjects with severe hepatic impairment, the (R)-enantiomer is more slowly eliminated from plasma.

## **6. PHARMACEUTICAL PARTICULARS**

### **6.1 List of excipients**

#### Tablet core

Lactose monohydrate; Sodium starch glycolate; Povidone K-30; Sodium starch glycolate;

SAHPRA CLINICAL TEMPLATE 07/2020  
Applicant/HCR: Accord Healthcare (Pty) Ltd  
Bicalutamide 150 Accord, Film coated tablet (Bicalutamide)  
Strength: 150 mg

### **FINAL PROFESSIONAL INFORMATION**

Magnesium stearate

#### **Film coating**

Hypromellose; Titanium dioxide; Macrogol 400

#### **6.2 Incompatibilities**

Not applicable.

#### **6.3 Shelf life**

2 years

Do not store at or below 25 °C.

Keep out of reach of children.

#### **6.4 Special precautions for storage**

This medicinal product does not require any special temperature storage conditions.

#### **6.5 Nature and contents of container**

Clear PVC/PVdC-Aluminium blister pack comprising strips of 5, 10, and 14 tablets to give pack sizes of 10, 20, 30, 40, 50, 80, 90, 100, 200 or 14, 28, 56, 84, 140 and 280 tablets.

Not all pack sizes may be marketed.

#### **6.6 Special precautions for disposal and other handling**

No special requirements.

Any unused medicinal product or waste material should be disposed of in accordance with local requirements.

SAHPRA CLINICAL TEMPLATE 07/2020  
Applicant/HCR: Accord Healthcare (Pty) Ltd  
Bicalutamide 150 Accord, Film coated tablet (Bicalutamide)  
Strength: 150 mg

**FINAL PROFESSIONAL INFORMATION**

**7. HOLDER OF CERTIFICATE OF REGISTRATION**

Accord Healthcare (Pty) Ltd  
Tuscany Office Park, Building 2  
6 Coombe Place,  
Rivonia,  
Johannesburg  
South Africa

**8. REGISTRATION NUMBER(S)**

54/21.12/0880

**9. DATE OF FIRST AUTHORISATION/RENEWAL OF THE AUTHORISATION**

22 February 2022

**10. DATE OF REVISION OF THE TEXT**

To be confirmed.